Although several EGFR tyrosine kinase inhibitors (EGFR-TKIs), such as erlotinib (Er), have been developed, acquired resistance to these therapies is a major challenge, limiting their long-term effectiveness for lung cancer [5, 6]. The gene discussed is EGFR; the disease is lung carcinoma.